Artiva Biotherapeutics, Inc. ARTV Cumulative Cost Basis
Cumulative Cost Basis at other companies
Other financials
Where this comes from
Reported directly by Artiva Biotherapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:PropertyPlantAndEquipmentGross.
The official record: Artiva Biotherapeutics, Inc.’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →
Ask your AI about Artiva Biotherapeutics, Inc.'s cumulative cost basis.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Artiva Biotherapeutics, Inc.'s cumulative cost basis?
- Artiva Biotherapeutics, Inc. (ARTV) reported cumulative cost basis of $15.32M in Q1 2026.
- How has Artiva Biotherapeutics, Inc.'s cumulative cost basis changed year-over-year?
- Artiva Biotherapeutics, Inc.'s cumulative cost basis increased by 12.7% year-over-year, from $13.59M to $15.32M.
- What is the long-term trend for Artiva Biotherapeutics, Inc.'s cumulative cost basis?
- Over 2 years (2023 to 2025), Artiva Biotherapeutics, Inc.'s cumulative cost basis has grown at a 13.9% compound annual growth rate (CAGR), from $11.63M to $15.08M.